The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19

Ya-dong Gao¹,², Ioana Agache³, Mübeccel Akdis⁴, Kari Nadeau⁵, Ludger Klimek⁶, Marek Jutel⁷,⁸, Cezmi A Akdis⁴#

1. Department of Allergology, Zhongnan Hospital of Wuhan University. Donghu Road 169, Wuhan 430071, Hubei, China
2. Hubei Province Key Laboratory of Allergy and Immunology, Wuhan University, Wuhan 430071, Hubei, China
3. Faculty of Medicine, Transylvania University, Brasov 500050, Romania.
4. Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Herman-Burchard Strasse 9, CH-7265, Davos, Switzerland
5. Sean N. Parker Center for Allergy and Asthma Research, Department of Medicine, Stanford University, Palo Alto, California 94305, USA.
6. Center for Rhinology and Allergology, An den Quellen 10, D-65183, Wiesbaden, Germany
7. Department of Clinical Immunology, Wrocław Medical University.
8. All-MED Medical Research Institute, Wrocław, Poland

#To whom correspondence should be addressed:

Cezmi A Akdis,
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich,
Herman-Burchard Strasse 9, Davos, Switzerland
Email: akdisac@siaf.uzh.ch
Tel: +41 81 810 0848
Abstract

The coronavirus disease 2019 (COVID-19) pandemic causes an overwhelming number of hospitalization and deaths with a significant socioeconomic impact. The vast majority of studies indicate that asthma and allergic diseases do not represent a risk factor for COVID-19 susceptibility nor cause a more severe course of disease. This raises the opportunity to investigate the underlying mechanisms of the interaction between an allergic background and SARS-CoV-2 infection. The majority of patients with asthma, atopic dermatitis, allergic rhinitis, chronic rhinosinusitis, food and drug allergies exhibit an overexpression of type 2 immune and inflammatory pathways with the contribution of epithelial cells, innate lymphoid cells (ILC), dendritic cells, T cells, eosinophils, mast cells, basophils and the type 2 cytokines interleukin (IL)-4, IL-5, IL-9, IL-13, and IL-31. The potential impact of type 2 inflammation-related allergic diseases on susceptibility to COVID-19 and severity of its course have been reported. In this review, the prevalence of asthma and other common allergic diseases in COVID-19 patients is addressed. Moreover, the impact of allergic and non-allergic asthma with different severity and control status, currently available asthma treatments such as inhaled and oral corticosteroids, short- and long-acting β2 agonists, leukotriene receptor antagonists and biologicals on the outcome of COVID-19 patients is reviewed. In addition, possible protective mechanisms of asthma and type 2 inflammation on COVID-19 infection, such as the expression of SARS-CoV-2 entry receptors, antiviral activity of eosinophils, cross-reactive T cell epitopes are discussed. Potential interactions of other allergic diseases with COVID-19 are postulated, including recommendations for their management.

Key words: angiotensin-converting enzyme 2, SARS-CoV-2, susceptibility, severity, mortality
1. Introduction

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected over 230 million people with a fatality of over 4.7 million people worldwide (1). Symptoms of COVID-19 are heterogeneous and its severity ranges from asymptomatic, mild, moderate, severe, and critical disease to death (2). SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) via its spike protein to enter host cells, and the process of cell entry is promoted by the host transmembrane protease serine 2 (TMPRSS2) that cleaves the spike protein into S1 and S2 fragments, thus enabling cellular membrane fusion (3, 4). Other molecules such as CD147 and CD26 are also potentially used by SARS-CoV-2 as receptors to enter human cells (3, 4). In addition, cell entry of SARS-CoV-2 is preactivated by proprotein convertase furin, reducing its dependence on target cell proteases for entry (5). Different expression patterns of these receptors in airway epithelial cells, bronchial biopsies and sputum cells has been reported in asthma(6-17).

Asthma and allergic diseases are usually driven by type 2 (T2) immune-inflammatory pathogenic mechanisms, with the contribution of epithelial cells, T2 innate lymphoid cells (ILCs), macrophages, NK-T cells, dendritic cells (DC), T helper (Th) 2 cells, T cells, eosinophils, mast cells (MCs) and basophils. Activation of Th2- and ILC2-pathways is at the core of T2 inflammation in asthma (18). T2 cytokines include interleukin (IL)-4, IL-5, IL-9, IL-13, and IL-31, acting in cooperation with epithelial-derived cytokines IL-33, IL-25 and TSLP (18, 19).

Different factors influencing the susceptibility, severity and mortality of COVID-19 have been identified, including demographic characteristics, comorbidities, and laboratory indicators (20, 21). A genetic predisposition to any allergic diseases was associated with reduced susceptibility to COVID-19 (22) and atopic status protects COVID-19 patients from severe disease (23). However, conflicting data have been reported about the prevalence of asthma in hospitalized COVID-19 patients. This has led to substantial investigations on the risk of asthma and the different phenotypes of asthma in COVID-19 susceptibility, impacts of asthma on COVID-19 severity and mortality, expression of ACE2 and other entry receptors for SARS-CoV-2 in different tissue and samples from patients with and without asthma and atopy. In addition, the potential impact of other allergic diseases and their treatments such as allergic rhinitis, atopic dermatitis, food allergy and drug allergy on COVID-19 have also been investigated. Other studies have focused on the modulation of strategies for the treatment of allergic diseases during COVID-19.
Several risk factors have been identified in the progression of COVID-19 into a severe and critical stage (20, 21). They can be listed as mechanisms that influence anti-viral mechanisms to cope with the virus itself and mechanisms that are responsible for tissue injury and severe disease (24). Type 2 immunity in allergic diseases and asthma influences many of these factors related to infection and severity of COVID-19 (25). In most cases these factors act together due to delays or weaknesses in controlling viral replication increases the viral load, infection of a higher number of cells and the eventual burden of inflammation and tissue injury. Factors that increase the risk of severe disease include old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung disease, heart, liver and kidney disease, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type-I interferon secretion capacity, and pregnancy (20). The development of a cytokine storm and endotheliitis, together with possible complications including acute respiratory distress syndrome, shock, disseminated coagulopathy, acute kidney injury, pulmonary embolism, and secondary bacterial pneumonia, may all underly severe COVID-19 (20). In the current review, we discuss all the aspects of the mutual relationship between asthma and allergies, and COVID-19 pathogenesis.

2. Asthma and COVID-19

2.1 Asthma and COVID-19 susceptibility

On the 19th of February 2020, our group reported the clinical characteristics of the first human-to-human contact series in Wuhan, China. Of notice, there were no asthma patients among the 140 hospitalized COVID-19 patients included in the study (26). A lower incidence of COVID-19 in asthma patients has been confirmed by several studies later. Another study in Wuhan reported the prevalence of asthma was 0.9% (5/548) in hospitalized COVID-19 patients (27). In 748 hospitalized COVID-19 patients in Paris, France, 4.8% had a history of asthma (28). Since then, a lower prevalence of asthma in COVID-19 was also reported in Israel (29), Italy (30), Saudi Arabia (31), Mexico (25), Brazil (32), Spain (33) (34) and Russia (35). On the contrary, a higher prevalence of asthma in COVID-19 patients was found in Switzerland (36), Strasbourg (37), France and UK (14.0%-17.9%) (38) at the early stage of the pandemic. A similar prevalence of asthma (6.6%) between COVID-19 patients and the general population (6.4%) was reported in Sweden (39). Conflicting data of asthma prevalence was reported in Korea (40-42) and USA (43-46). The COVID-19 incidence was not significantly different in active and inactive asthma, suggesting that asthma status does not increase the risk of COVID-19 infection (45). A systemic review reported great variability of asthma prevalence in COVID-19 (1.15-16.9%) (47). This variability of asthma prevalence observed in different countries may be caused by several factors, such as adherence to asthma therapy, control status of asthma,
availability of medication, enforcement of lockdown and social distance, prevalence of obesity, diabetes, and other comorbidities and the diagnostic PCR test frequency for SARS-CoV-2 (48). Severe asthma was not regarded initially as a risk factor for SARS-CoV-2 infection (49), even in severe asthma patients requiring ongoing biologic therapy targeting type 2 inflammation (50, 51). The reported prevalence of asthma in COVID-19 is listed in Table 1.

2.2 Preexisting asthma and the risk for hospitalization, severity and mortality of COVID-19

Most studies did not identify preexisting asthma as a risk factor for hospitalization of COVID-19. Asthma did not increase the risk of COVID-19-related hospitalization (43) and the time to resolution of COVID-19 symptoms, particularly lower respiratory tract symptoms (52). A recent study in USA also confirmed that asthma was not a risk factor for hospitalization of COVID-19 (52). Moreover, allergic asthma was associated with a lower hospitalization risk due to COVID-19 when compared to non-allergic asthma (OR = 0.52, 95% CI: 0.28-0.91) (52). A multivariate analysis found that asthma patients of male sex, Asian race, and with comorbid chronic obstructive pulmonary disease (COPD) were associated with increased risk, whereas those solely using short-acting β2 agonist (SABA) to relieve symptoms were associated with decreased risk for hospitalization of COVID-19 (53). Active asthma and those without medication to control asthma were associated with a higher risk of COVID-19 hospitalization (45). In contrast, the Sweden national cohort identified asthma as a risk factor for hospitalization but not for mortality (39). In a systematic review including 131 studies and 410,382 COVID-19 patients, asthma was not identified as a risk factor for hospitalization (47).

In the UK national multicenter prospective cohort and age-stratified study including 75,463 COVID-19 patients, those with asthma (≥ 16 years old) were associated with a higher risk of receiving critical care including ventilation support and oxygen therapy when compared to those without asthma or other preexisting respiratory conditions (54). Active asthma was associated with a higher rate of intensive respiratory support and ICU admission, especially in patients without medication (45). In patients aged 16-49 years, those with severe asthma (defined as the need for inhaled corticosteroids plus long-acting β2 agonist plus another maintenance therapy) had a significant increased risk of mortality compared to subjects without asthma (adjusted HR 1.17, 95% CI: 0.73-1.86). Severe asthma patients aged 50 and older were associated with a higher risk of death compared to those asthma patients not requiring therapy (aHR 1.24, 95%CI: 1.04-1.49) (54).

In the above-mentioned systematic review, asthma was not identified as a risk factor of severe disease, intensive care unit (ICU) admission and intubation, but rather associated with a lower risk of death of COVID-19 (RR 0.65, 95% CI: 0.43-0.98) (47). Other studies found that asthma was not associated with risk of ICU admission and mortality of COVID-19 (46, 55). In contrast, a Korean
cohort of 725 COVID-19 patients suggested that asthma was associated with a severe clinical outcome (aOR 1.62), which was mainly caused by non-allergic asthma (aOR 4.09) but not allergic asthma(40). This is contrary to another Korean study which showed that asthma was not associated with severe clinical outcomes after adjustment of potential confounding factors(41). Obesity, chronic kidney disease, and marital status might be risk factors for ICU admission, and male sex and cardiovascular disease might be risk factors for mortality in COVID-19 patients with previous asthma (53). It is worth noting that these factors are also identified in the general population with COVID-19.

Severe asthma did not increase the risk of severe outcomes of COVID-19, as reported in studies from Italy(49, 56) and USA(52). Asthma control status was not associated with an increased risk of COVID-19-related death(45). However, severe patients receiving biological treatment were associated with a higher risk of hospitalization and invasive mechanical ventilation(51). In 50 years and older COVID-19 patients, severe asthma significantly increased the risk of death (aHR 1.96, 95% CI: 1.25-3.08)(54). This discrepancy in results may come from the distinct criteria of severe asthma and the index of outcomes in these studies. On the other hand, available data showed that SARS-CoV-2 did not induce severe asthma exacerbation(37, 57). Studies regarding the impact of asthma on the hospitalization, severity and mortality of COVID-19 are summarized in Table 2.

In children, the prevalence of asthma in COVID-19 patients was lower compared to that in the pediatric population (58-60). Asthma was not associated with increased severity and mortality of COVID-19 (61). On the other hand, improved asthma control and improved lung function were observed in children with asthma during COVID-19 pandemic, which may be due to reduced exposure to asthma triggers and increased adherence to asthma treatments (62). A general trend of clinical improvement and a reduction in the use of on-demand and basal therapy in allergic children was observed during the lockdown(63). The impact of asthma on COVID-19 and lockdown due to COVID-19 on asthma in children is summarized in Table 3.
2.3 The effect of asthma treatments on COVID-19

Several studies on the effect of currently available asthma treatments on the susceptibility, hospitalization, disease severity, and mortality of COVID-19 are summarized in Table 4.

2.3.1 Inhaled corticosteroids (ICS)

Asthma patients on ICS maintenance treatment had a higher expression level of ACE2 in large airway epithelium than those not treated with ICS and healthy controls (64). However, ongoing use of ICS did not increase the risk of hospitalization due to COVID-19 in asthma patients (43). In another study, asthma patients on high-dose ICS treatment were found to have a higher death rate for COVID-19 compared to those only treated with SABAs (65). Interestingly, in COVID-19 patients aged 50 years and older and with asthma, treatment with ICS alone within 2 weeks of hospital admission was associated with reduced mortality risk compared to those without an underlying respiratory condition (adjusted HR 0.86, 95% CI 0.80-0.92), and those who were not treated with ICS had no reduction in mortality (54). Considering the fact that an increased risk of death has been demonstrated in the same study in severe asthma patients (ICS+ LABA+ another maintenance therapy) (54) the use of ICS alone may represent a protective effect for COVID-19 mortality. Another study also confirmed that ICS use before hospitalization did not increase SARS-CoV-2 infection(55). In fact, the ICS ciclesonide has been shown to inhibit SARS-CoV-2 RNA replication in cell cultures (66). Studies on the effects of administration of ICS at an early stage of COVID-19 are controversial and inconclusive (67). In summary, severe asthma, but not ICS, may be associated with an increased risk of worse outcomes in COVID-19 patients with asthma.

2.3.2 Oral corticosteroids (OCS)

Use of OCS to relieve the acute exacerbation or reach symptom control without other alternative treatments indicates severe asthma. OCS usage during the last 12 months did not increase the risk of COVID-19 infection in asthma patients (29, 68). However, most studies indicate that OCS usage increased the COVID-19 severity and mortality. OCS usage within 2 weeks prior to hospital admission was associated with a higher risk of death for COVID-19 patients with asthma (HR = 1.25, 95% CI 1.08-1.44), as demonstrated in the OpenSAFELY study (69). Recent usage (within 120 days), but not former usage of OCS, was a risk factor for the development of moderate/severe COVID-19 and the all-cause mortality (68). Another study also demonstrated that OCS usage before hospitalization was associated with increased ICU admission and death of COVID-19 (55).

The benefits of systemic corticosteroids may outweigh the risk of severe COVID-19 outcomes for COVID-19 patients with preexisting asthma relying on OCS to reach symptom control, (70), e.g.,
restores impaired antiviral immunity in asthma (71). Moreover, uncontrolled asthma was associated with increased ICU admission and intensive respiratory support (45), whereas well-controlled asthma was not at increased risk of COVID-19-related death (69). In this context, OCS ought to be continued to maintain asthma control or relieve the asthma exacerbation induced by COVID-19 (72), but with minimal dosage (73).

2.3.3 Long-acting β2 agonists (LABA)

As recommended by most asthma guidelines, LABA should not be used in asthma patients without combination with ICS, therefore, there is no evidence about the impact of LABA usage alone on COVID-19 susceptibility and outcomes. Ongoing therapy with combination of ICS and LABA represents a more severe asthma compared to patients on solely ICS treatment. In a UK national cohort study, asthma patients (16-49 years) treated with ICS plus LABA had a HR of 1.02 (95% CI 0.67-1.54), whereas those treated with ICS plus LABA plus another maintenance therapy had a HR of 1.96 for mortality of COVID-19 (54). In contrast, Korean data involving 218 asthma patients showed that ICS+LABA treatment in the last 12 months did not affect the hospitalization duration, ICU admission and death rates of COVID-19 (74). Asthma patients treated with ICS+LABA had a higher hospital admission rate than those with ICS usage alone, but not those without ICS usage, whereas asthma patients treated with ICS+LABA were associated with a higher ICU admission rate compared to those without ICS or solely ICS usage (43).

2.3.4 Leukotriene receptor antagonists (LTRA)

The LTRA montelukast is a potent inhibitor of the main protease of SARS-CoV-2 (75). In elderly asthma patients, long-term treatment of montelukast was associated with a reduction in infection and hospitalization rate compared to those without montelukast treatment. Montelukast treatment (10 mg/day) also significantly reduced clinical deterioration rate of COVID-19 (76). The same observation was not found in an Israel study that montelukast was not associated with decreased infection of COVID-19 (29) and in a Korean study showing that LTRA was not associated with increased mortality in asthma patients (74). Other possible beneficial effects of montelukast to COVID-19 including antiviral properties, prevention of endotheliitis and neurological disorders linked to SARS-CoV-2, improvement of atherogenic vascular inflammation, limitation of the ischemia/reperfusion phenomenon, improvement of respiratory symptoms, limitation of the cytokine storm, mitigation of acute respiratory distress syndrome, antioxidant properties, and anti-fibrosis effects, as suggested by Barre et al. (77). Nevertheless, further studies are warranted to confirm the beneficial effects of montelukast in the treatment of COVID-19.
2.3.5 Short-acting β2 agonists (SABA)

Beta-adrenergic blockers have been suggested to be beneficial for COVID-19 patients as they can potentially reduce ACE2 and CD147 expression, inhibiting inflammation, pulmonary edema, embolism, and mucus hypersecretion (78). Thus, beta-agonists may be harmful to COVID-19 patients. However, inhaled SABA solely indicates a relatively well-controlled asthma, which is associated with a reduced risk of COVID-19 when compared to uncontrolled asthma (45). In COVID-19 patients aged 16-49 years, asthma treated with inhaled SABA only was not associated with increased mortality from COVID-19 (HR 0.99, 95% CI: 0.61-1.58) (54). Asthma patients prescribed inhaled SABA only in the previous 4 months had a lower mortality of COVID-19 compared to those prescribed high-dose ICS but had no significant difference in mortality compared to those prescribed low or medium-dose ICS (65). Another Korean study showed that oral SABA in the previous year was associated with an increased medical cost burden in COVID-19 (74).

2.3.6 Biologicals

Biologicals are currently widely used for the treatment of severe allergic or eosinophilic asthma. Data from the Belgian Severe Asthma Registry showed that treatment with biologicals for severe asthma was not a risk factor for SARS-CoV-2 infection nor more severe COVID-19 (79). In severe asthma patients with COVID-19, biological treatment was not a risk factor for COVID-19(50) or its severity and mortality (68, 80), and there were no significant differences among the different biologic drugs used (80). However, a study conducted in the Netherlands revealed a poor outcome of COVID-19 in asthma patients treated with biologicals (51). Single case reports for asthma patients treated with Omalizumab (81), Mepolizumab (82), Benralizumab (83) have been reported with a good outcome of COVID-19. Noticeably, a severe asthma patient treated with dupilumab presented with modest antibody response against SARS-CoV-2 (84), suggesting further studies are needed to elucidate the safety of dupilumab during COVID-19. Delayed and/or impaired type I interferon response in will lead to severe COVID-19 (20), whereas the anti-IgE monoclonal antibody Omalizumab could enhance antiviral responses of plasmacytoid dendritic cells (pDCs) by promoting the interferon production in asthma patients (85). Anti-IL-5/IL-5R treatment reduces eosinophilia, which was identified as a protective factor for COVID-19 infection and severity (86). Nonetheless, further evidence with a large sample size is needed to elucidate the effects of biologicals on the incidence and severity of COVID-19 as well as the serological response in severe asthma patients.
2.4 Possible mechanisms underlying asthma and COVID-19 prevalence and severity

2.4.1 Expression of ACE2 and TMPRSS2 in asthma

Reduced expression of ACE2 has been reported in airway epithelial cells and bronchial biopsies from asthma patients (6, 7). On the other hand, increased (8) or unchanged ACE2 expression (9, 10) has also been reported in bronchial biopsies (8, 9) or sputum cells (10) from asthma patients when compared to healthy controls. TMPRSS2 expression in the sputum cells (10) and bronchial biopsies (9) was not significantly different between asthma patients and healthy controls, and there was a positive correlation with the expression of TMPRSS2 and ACE2 (10). Moreover, in asthma patients, male sex, African American race, and history of diabetes mellitus were associated with a higher expression of ACE2 and TMPRSS2, whereas use of ICS was associated with a lower expression of ACE2 and TMPRSS2 in sputum cells (10). In asthma patients, ACE2 expression is decreased in those with high IgE sensitization or after allergen challenge in nasal and bronchial epithelium (11). In addition, reduced expression and activity of ACE2 were observed in lung tissue of a HDM-induced mice model (12). These data suggest that type 2 inflammation might have an inhibitory effect on ACE2 expression in airway epithelium. Several studies found that IL-13 significantly reduced ACE2 (7, 11, 13, 14) and increased TMPRSS2 expression in airway epithelial cells (13, 14), and ACE2 expression was negatively associated with, whereas TMPRSS2 expression was positively associated with type 2 cytokines (13, 14). ACE2 expression in the bronchial epithelium was higher in asthma patients with lower peripheral blood eosinophils, an indicator of type 2-low airway inflammation. ACE2-high asthma patients were characterized by an overlapping type I and II interferon signature, significant T cell recruitment and activation in bronchial lavages, and also risk factors for severe COVID-19 such as male gender, hypertension comorbidity, and peripheral blood lymphocytopenia (15). A recent study found that ACE2 level from the sputum of severe asthma patients was significantly higher than that of mild-moderate asthma patients, and TMPRSS2 levels in bronchial biopsies were positively correlated with blood neutrophils (16). This finding may partly explain the worse outcome observed in severe asthma patients.
2.4.2 Expression of other receptors for SARS-CoV-2 in asthma patients

Furin levels are not different in bronchial biopsies between asthma patients and healthy controls (9), but are higher in sputum from severe asthma than from mild-moderate asthma patients, and are positively associated with sputum neutrophils (16). In addition, furin levels in bronchial brushings are positively correlated with blood neutrophils, suggesting that furin may contribute to the increased viral load and outcomes in neutrophilic severe asthma (16).

Basigin (CD147) acts as a binding receptor for the spike protein of SARS-CoV-2. ACE2 and CD147 receptors do not coexist in the airway epithelium, suggesting that CD147 acts as an alternative entry site for SARS-CoV-2 (8). The expression level of CD147 in airway epithelia (8, 17) as well as in blood (8) is not different between asthmatics and non-asthmatics. These data suggests that CD147 does not account for the lower prevalence of asthma in COVID-19.

2.4.3 Antiviral activity of eosinophils

We proposed that eosinopenia can be an early biomarker of COVID-19 (26). In addition, eosinopenia is also a risk factor for severe outcomes of COVID-19, including death (21, 86, 87), especially in those with persistent eosinopenia (21, 86). Eosinophil count was inversely related to inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) (21, 87), blood urea nitrogen (21), liver function and serum amyloid A (21), and positively correlated with lymphocyte count (21, 87). Patients with severe COVID-19 disease had lower eosinophil levels during hospitalization compared with patients with mild or asymptomatic disease, independent of asthma status (52). Eosinopenia is more common in COVID-19 than influenza pneumonia and other pneumonia (86). By contrast, eosinophilia has also been suggested to be a protective factor for SARS-CoV-2 infection both in adults and in children (88). Asthma patients with pre-existing eosinophilia (absolute eosinophil count, AEC ≥ 150 cells/μl) had a lower risk for COVID-19 admission, and asthma patients with eosinophilia during hospitalization due to COVID-19 had lower mortality compared to those whose AEC remained < 150 cells/μl (89). Eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) are eosinophil-derived enzymes that can neutralize the virus (60). The antiviral activity of eosinophils may partly contribute to the lower prevalence of allergic asthma in COVID-19 (90). In asthma patients, eosinophil activation in viral respiratory infections is likely a double-edged sword causing both acute exacerbation of asthma and protection against serious outcomes of viral infection such as SARS-CoV-2 (91). However, no severe outcomes for COVID-19 were reported in patients treated with anti-IL-5/R monoclonal antibodies, such as mepolizumab, even with eosinopenia at symptom presentation (92).
2.4.4 Cross-reactive T-cell epitopes between SARS-CoV-2 and allergens

A previous study identified cross-reactive T cell epitopes between influenza and allergens, which may protect against allergen-induced asthma by CD4⁺ and CD8⁺ effector-memory T cells (93). Similarly, bioinformatic approaches have identified potentially cross-reactive allergen- and SARS-CoV-2-T cell epitopes, highlighting an important role of MHC class I inhalant allergens. These results indicate that asthma patients may be more affected by the heterologous immune response against SARS-CoV-2. In asthma patients sensitized to one of the predicted aeroallergens, the similarities with the SARS-CoV-2 proteome may be protective by preventing an overwhelming type 1 response and the accompanying cytokine storm (94).

2.4.5 Other potential immunological mechanisms

Farne and Singanayagam proposed six rationales to explain the lower prevalence and relatively improved outcome of COVID-19 patients with asthma: 1) lower expression of viral receptors in the airway epithelium of asthma patients; 2) maintenance of ICS confers protection; 3) relatively younger age and/or absence of other comorbidities; 4) chronic inflammation in asthma induces immune tolerance against hyperinflammation; 5) reduced viral exposure due to more strict adherence of social distancing measures by asthma patients; 6) mucus hypersecretion may prevent viral penetration far enough to gain access to airway epithelial cells (95). Of note, children admitted to a hospital due to an asthma attack decreased dramatically during COVID-19, and better adherence to ICS, improved air quality and school closure may have contributed to this reduction (96). Mast cells also have high antiviral activity owing to their production of interferons and other antiviral mediators (57).

3 Allergic rhinitis (AR) and chronic rhinosinusitis with nasal polyps (CRwNP)

Nasal symptoms in COVID-19 present similarities to those of AR during the pollen season, increasing the complexity of the diagnosis (97). Moreover, the prevalence of the common cold in winter will further complicate the differentiation between perennial AR and COVID-19 (98). Seasonal AR had a higher sino-nasal outcome test (SNOT)-22 score. Blow of nose and sneezing were more common and severe in seasonal AR, whereas cough and olfactory disorders were more common and severe in COVID-19 (99). It is noted that lockdown during pollen season not only reduced COVID-19 infection but also the severity of seasonal AR (100).

The prevalence of AR in hospitalized COVID-19 was not higher than in the general population in early reports from Wuhan (9.7%) (26, 101), consistent with a recent finding in Israel (29). However, the data are not consistent with that reported in Korea, where AR was associated with a higher incidence of COVID-19 (40). The same study identified current AR as a risk factor for severe clinical
outcomes (OR=1.40) (40). COVID-19 patients with AR had a higher incidence of asthma than those without AR (101). However, co-existence of AR and asthma was not a risk factor for hospitalization of COVID-19 in children (58).

AR was not a risk factor for hospitalization (43, 102) or longer hospital stay (102) in adults as well as in children (58). This was similar also in other severe outcomes such as severe disease, mechanical ventilation, ICU admission and mortality for COVID-19 patients (102).

The nose is the main entry site for SARS-CoV-2 and so the expression of ACE2 and other SARS-CoV-2 entry receptors has been investigated in nasal tissue biopsies or in in vitro cultured human nasal epithelial cells (HNECs). Both the mRNA and protein expression of ACE2 was not altered in nasal tissue of AR patients compared to healthy individuals (101). However, in HNECs, the Th2 cytokines interleukin (IL)-4 and IL-13 reduced ACE2 expression, whilst interferon (IFN)-α and IFN-γ dramatically increased ACE2 expression (101). In CRwNP patients, a decreased expression of ACE2 and TMPRSS2 was found in olfactory mucosa (103) and a decreased expression of ACE2 in nasal polyps (104). These data indicate a possible protecting effect of type 2 inflammation on AR and CRwNP patients against COVID-19.

Proper treatment of AR may prevent the spread of SARS-CoV-2 (105). Face masks effectively mitigated the symptom burden in nurses with AR, (106) and thus should be recommended to all AR patients during the COVID-19 pandemic. Based on a questionnaire conducted by ARIA members, intranasal corticosteroids (INCS) can be continued in COVID-19 patients with AR (107). INCS does not prevent the development of olfactory and gustatory dysfunction in COVID-19 patients, however, it may reduce the severity and duration of these symptoms (108). Corticosteroids reduced the expression of ACE2 but not TMPRSS2 in HNECs (109), which also supports the continuation of INCS use in AR patients during COVID-19. Ongoing allergen immunotherapy should be continued in AR patients without COVID-19 to avoid deterioration of clinical symptoms during COVID-19 (110). New sublingual immunotherapy but not SCIT can be started in selected AR patients (105).

4 Atopic dermatitis (AD)

Limited studies have reported the prevalence of AD in COVID-19. In a Korean national cohort study, AD was not identified as a risk factor for infection and severity of COVID-19 (40). In an Israel study, AD prevalence was also similar between COVID-19 negative and positive individuals (29). Similarly, AD was not a risk factor for hospitalization of COVID-19 in children (58).

Expression of ACE2, TMPRSS2 and other related molecules in the skin, both from healthy controls and from AD patients, indicate that the skin may be a potential entry site for SARS-CoV-2 (8). No significant difference of ACE2 expression was found among skin tissues from healthy controls, lesional skin and non-lesional skin from AD patients. The expression of TMPRSS2 was higher in non-
lesional skin than in lesional skin from AD and in the skin from healthy controls (8). Further research is warranted to elucidate the link between the expression of SARS-CoV-2 related receptors in the skin and skin manifestations of SARS-CoV-2, such as pseudo-chilblains, erythematous maculopapular rashes, vesicular rashes and urticarial rashes (11).

Dupilumab is an anti-IL-4 receptor α monoclonal antibody for the treatment of moderate-severe AD and potentially other type 2 inflammations such as allergic asthma and chronic rhinosinusitis with nasal polyps (CRwNP). The risk of use of dupilumab during COVID-19 pandemic has been discussed (112). The European Task Force for AD recommended the continuation of the use of dupilumab in AD during COVID-19 (113), since recent evidence showed that it does not increase the risk of infection and worsen the clinical course of COVID-19 (114). The interruption of dupilumab and other immunomodulatory biologicals has not been suggested because stopping these drugs may exacerbate all of type 2 inflammation-related diseases such as AD, asthma, AR and CRwNP (113). The effect of dupilumab on the expression of ACE2 and other entry receptors for SARS-CoV-2 as well as the immune responses to SARS-CoV-2 infection need to be further investigated. Other medications used for the treatment of AD, including topical steroids and calcineurin inhibitors, did not increase the severity of COVID-19 (115).

5 Food allergy (FA)

No patients with a history of FA were reported in our first 140 cases of COVID-19 in Wuhan (26). Interestingly, atopy (defined as those with eczema, AR, and FA) was associated with a lower hospitalization rate for COVID-19 patients (116). In children, food allergen sensitization did not increase the hospitalization rate due to COVID-19(58). To the best of our knowledge, the expression of ACE2 and other SARS-CoV-2 receptors in FA patients have not been reported to date, nor the outcome of COVID-19 patients with FA. The COVID-19 pandemic and self-isolation/quarantine have been reported to have a negative impact on the quality of life of children and adolescents with food allergy due to the limitation in the available medical care and accessing “safe” food (117). However, an Israel survey found that the reported food allergic reactions during COVID-19 lockdown were lower than that in the previous 3 months. Young age, history of allergic reactions, and allergy to multiple allergens were identified as risk factors for FA in preschool children (118). Proper management of FA during COVID-19, including FA diagnosis, FA prevention, management of anaphylaxis, oral food challenge and oral immunotherapy have been discussed elsewhere (119).
6 Drug allergy (DA)

Sixteen COVID-19 patients with a self-reported history of DA have been reported in our 140 cases(26). A systemic cytokine storm was suggested to promote activation of monocytes, macrophage and cytotoxic CD8’ T cells in severe COVID-19 patients, which in turn may impact the development of maculopapular drug rashes (MDR) (120). Skin biopsies might be necessary to differentiate viral exanthem from drug-induced exanthem in COVID-19 patients(121). No SARS-CoV-2 was detected in skin biopsies of MDR in COVID-19 patients(120). However, to the best of our knowledge, there are no reports on the expression of ACE2 and other SARS-CoV-2 receptors in DA patients, and the outcome of COVID-19 patients with DA. Most of the treatments for COVID-19 are adapted from those for influenza or acquired immunodeficiency syndrome (AIDS), albeit none of these treatments proved effective in clinical trials. A comprehensive review highlighted published information on the diagnosis and management of drug hypersensitivity reactions to current and candidate off-label drugs for COVID-19 and relevant recommendations (122). Only those with a history of hyperreactivity to vaccines may be excluded from COVID-19 vaccination. Strategies to prevent, diagnose and manage severe allergic reactions to COVID-19 vaccines have been stated in EAACI position papers (123-125) (Table 5) and so will not be discussed in this review.

7 Chronic urticaria

The COVID-19 pandemic has a critical impact on patients with chronic urticaria (CU), including reduced patient referrals and clinical hours, and a shift towards telecommunication between the patient and physician. Moreover, cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab were less used during the COVID-19 pandemic. CU does not seem to affect the disease course of COVID-19; however, CU exacerbation was reported in almost 1/3 of patients with COVID-19(126). Omalizumab is approved for the treatment of chronic refractory urticaria. A recent report suggests that Omalizumab did not worsen the disease course of COVID-19 in seven cases with chronic spontaneous urticaria(127). The risk of discontinuation of Omalizumab on the susceptibility and disease course of COVID-19 was not reported. Omalizumab has been reported to be used to prevent anaphylactoid reactions related to COVID-19 vaccines(128).
8 Allergen immunotherapy (AIT) and COVID-19

AIT reduces Th2 responses and induces Treg and Breg cell responses. As there is a potential protecting effect driven by a Th2 response and inflammatory cytokine storm associated with Th1 responses in COVID-19, AIT should be discontinued in confirmed COVID-19 patients (73, 129). AIT, both SCIT and SLIT, should be continued in noninfected individuals during the COVID-19 pandemic (129), since delayed SCIT with aeroallergen during the COVID-19 pandemic resulted in deteriorated symptom scores and life quality of AR and asthma (110). In patients recovered from COVID-19 or with a sufficient SARS-CoV-2 antibody response after (asymptomatic) disease, AIT can be started or continued as planned (129). There are no reports on whether a history of AIT will reduce the risk of infection and severe outcome in COVID-19 patients with AR and/or allergic asthma.

9 Handling of allergic diseases during COVID-19

Different guidelines and position papers have been released by EAACI to address COVID-19 issues on pediatric allergy management, chronic rhinosinusitis, and the organization of an allergic clinic. A consensus was reached on the use of INCS, systemic corticosteroids, biologicals and surgery by expert allergists (130-133) (Table 5).

10 Conclusions

Allergic asthma is generally associated with a lower risk of infection, hospitalization, severe course of disease and mortality due to COVID-19. Uncontrolled severe asthma, especially in patients older than 50 years, may result in worse disease outcome. Treatments for asthma, such as ICS+LABA, LTRA, SABA and biologicals, are not associated with worse outcome of COVID-19. Recent usage of OCS and uncontrolled asthma represent risk factors for progression to a more severe disease. Both AR and AD are not identified as risk factors for infection, hospitalization, and severe outcomes of COVID-19. There is limited evidence on the risk of FA and DA on the infection and outcomes of COVID-19. Reduced expression of entry receptors for SARS-CoV-2 in airway epithelium, antiviral activity of eosinophils, cross-reactive T-cell epitopes between SARS-CoV-2 and allergens may all contribute to the protective effect of type 2 inflammation. COVID-19 may cause acute exacerbation of asthma and sometimes may be complicated with seasonal AR. AIT should be discontinued in confirmed COVID-19 patients and can be resumed in uninfected individuals or those recovered from COVID-19.
Funding

No.

Acknowledgements

We thank Dr. Laura Alberch for her help with language editing.

Conflicts of interest statement: the authors declared no conflicts of interest.
**Abbreviations**

ACE2: Angiotensin-converting enzyme 2  
AD: Atopic dermatitis  
AEC: Absolute eosinophil count  
AIDS: Acquired immunodeficiency syndrome  
AIT: Allergen immunotherapy  
aHR: Adjusted hazard ratio  
aOR: Adjusted odds ratio  
AR: Allergic rhinitis  
ARIA: Allergic Rhinitis and its Impact on Asthma  
CD: Cluster determinants  
CI: Confidence interval  
COPD: Chronic obstructive pulmonary disease  
COVID-19: Coronavirus disease 2019  
CRS: Chronic rhinosinusitis  
CRwNP: Chronic rhinosinusitis with nasal polyps  
DA: Drug allergy  
EAACI: The European Academy of Allergy and Clinical Immunology  
FA: Food allergy  
HNECs: Human nasal epithelial cells  
HR: Hazard ratio  
hsCRP: High-sensitivity C-reactive protein  
ICS: Inhaled corticosteroids
ICU: Intensive care unit

IgE: Immunoglobulin E

IL-: Interleukin

ILC: Innate lymphoid cells

INCS: Intranasal corticosteroids

LABA: Long-acting beta-agonists

LTRA: Leukotriene receptor antagonists

PCR: Polymerase chain reaction

SABA: Short-acting beta-agonists

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

SCIT: Subcutaneous immunotherapy

SLIT: Sublingual immunotherapy

SNOT-22: Sino-nasal outcome test-22

RR: Relative risk

Th: Helper T cells

TMPRSS2: Transmembrane protease serine 2

UK: United Kingdom

USA: United States of America
References

1. World Health Organization (WHO). Coronavirus disease (COVID-19) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed Jul 17, 2021
2. Dong, X., Cao, Y. Y., Lu, X. X., et al. 2020. Eleven faces of coronavirus disease 2019. Allergy 75: 1699-709
3. Riggioni, C., Comberiati, P., Giovannini, M., et al. 2020. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy 75: 2503-41
4. Sokolowska, M., Lukasik, Z. M., Agache, I., et al. 2020. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy 75: 2445-76
5. Shang, J., Wan, Y., Luo, C., et al. 2020. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117: 11727-34
6. Wark, P. A. B., Pathinayake, P. S., Kaiko, G., et al. 2021. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma. Respirology 26: 442-51
7. Song, J., Zeng, M., Wang, H., et al. 2020. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy 76:483.
8. Radzikowska, U., Ding, M., Tan, G., et al. 2020. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 75:2829.
9. Bradding, P., Richardson, M., Hinks, T. S. C., et al. 2020. ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19. J Allergy Clin Immunol 146: 208-11
10. Peters, M. C., Sajuthi, S., Deford, P., et al. 2020. COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. Am J Respir Crit Care Med 202: 83-90
11. Jackson, D. J., Busse, W. W., Bacharier, L. B., et al. 2020. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 146: 203-6 e3
12. Fukuda, A., Toyoshima, S., Yamada, S., et al. 2021. Enzymatic activity of ACE2 regulates type 2 airway inflammation in mice. Allergy 76: 1913-7
13. Kimura, H., Francisco, D., Conway, M., et al. 2020. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol 146: 80-8 e8
14. Sajuthi, S. P., Deford, P., Li, Y., et al. 2020. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun 11: 5139
15. Camilo, M., Gauthier, M., Kaminski, N., et al. 2020. Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype. J Allergy Clin Immunol 146: 315-24 e7
16. Kermani, N. Z., Song, W. J., Badi, Y., et al. 2021. Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma. Respir Res 22: 10
17. Matusiak, M., Schurch, C. M. 2020. Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics. Respir Res 21: 252
18. Akdis, C. A., Arkwright, P. D., Bruggen, M. C., et al. 2020. Type 2 immunity in the skin and lungs. Allergy 75: 1582-605
19. Han, X., Krempski, J. W., Nadeau, K. 2020. Advances and novel developments in mechanisms of allergic inflammation. Allergy 75: 3100-11
20. Gao, Y. D., Ding, M., Dong, X., et al. 2021. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy 76: 428-55
21. Zhang, J. J., Cao, Y. Y., Tan, G., et al. 2021. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. *Allergy* 76: 533-50
22. Larsson, S. C., Gill, D. 2021. Genetic predisposition to allergic diseases is inversely associated with risk of COVID-19. *Allergy* 76: 1911-3
23. Scala, E., Abeni, D., Tedeschi, A., et al. 2021. Atopic status protects from severe complications of COVID-19. *Allergy* 76: 899-902
24. Azkur, A. K., Akdis, M., Azkur, D., et al. 2020. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy* 75: 1564-81
25. Skevaki, C., Karsonova, A., Karaulov, A., et al. 2020. Asthma-associated risk for COVID-19 development. *J Allergy Clin Immunol* 146: 1295-301
26. Zhang, J. J., Dong, X., Cao, Y. Y., et al. 2020. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 75: 1730-41
27. Li, X., Xu, S., Yu, M., et al. 2020. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 146: 110-8
28. Beurnier, A., Jutant, E. M., Jevnikar, M., et al. 2020. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. *Eur Respir J* 56:2001875
29. Green, I., Merzon, E., Vinker, S., et al. 2021. COVID-19 Susceptibility in Bronchial Asthma. *J Allergy Clin Immunol Pract* 9: 684-92 e1
30. Caminati, M., Lombardi, C., Micheletto, C., et al. 2020. Asthmatic patients in COVID-19 outbreak: Few cases despite many cases. *J Allergy Clin Immunol* 146: 541-2
31. Shabravishi, M., Al-Gethamy, M. M., Naser, A. Y., et al. 2020. Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia. *PLoS One* 15: e0237130
32. Rezende, L. F. M., Thome, B., Schweitzer, M. C., et al. 2020. Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil. *Rev Saude Publica* 54: 50
33. Barroso, B., Valverde-Monge, M., Canas Jose, A., et al. 2020. Prevalence, Characteristics, and Outcome of Asthmatic Patients With Type 2 Diseases in Hospitalized Patients With COVID-19 in Madrid, Spain. *J Investig Allergol Clin Immunol* 30: 382-4
34. Borobia, A. M., Carcas, A. J., Arnalich, F., et al. 2020. A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. *J Clin Med* 9:1733.
35. Avdeev, S., Moiseev, S., Brovko, M., et al. 2020. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. *Allergy* 75: 2703-4
36. Thiabaud, A., Iten, A., Balmelli, C., et al. 2021. Cohort profile: SARS-CoV-2/COVID-19 hospitalised patients in Switzerland. *Swiss Med Wkly* 151: w20475
37. Grandbastien, M., Piotin, A., Godet, J., et al. 2020. SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. *J Allergy Clin Immunol Pract* 8: 2600-7
38. Morais-Almeida, M., Pite, H., Aguiar, R., et al. 2020. Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review. *Int Arch Allergy Immunol* 181: 680-8
39. Bergman, J., Ballin, M., Nordstrom, A., et al. 2021. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. *Eur J Epidemiol* 36: 287-98
40. Yang, J. M., Koh, H. Y., Moon, S. Y., et al. 2020. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. *J Allergy Clin Immunol* 146: 790-8
41. Kim, S., Jung, C. G., Lee, J. Y., et al. 2021. Characterization of asthma and risk factors for delayed SARS-CoV-2 clearance in adult COVID-19 inpatients in Daegu. *Allergy* 76: 918-21
42. Choi, H. G., Wee, J. H., Kim, S. Y., et al. 2021. Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean Disease Control and Prevention. Allergy 76: 921-4
43. Chhiba, K. D., Patel, G. B., Vu, T. H. T., et al. 2020. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol 146: 307-14 e4
44. Lovinsky-Desir, S., Deshpande, D. R., De, A., et al. 2020. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol 146: 1027-34 e4
45. Huang, B. Z., Chen, Z., Sidell, M. A., et al. 2021. Asthma Disease Status, COPD, and COVID-19 Severity in a Large Multiethnic Population. J Allergy Clin Immunol Pract in press DOI:10.1016/j.jaip.2021.07.030
46. Lieberman-Cribbin, W., Rapp, J., Alpert, N., et al. 2020. The Impact of Asthma on Mortality in Patients With COVID-19. Chest 158: 2290-1
47. Liu, S., Cao, Y., Du, T., et al. 2021. Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract 9: 693-701
48. Kow, C. S., Capstick, T., Hasan, S. S. 2021. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? Allergy 76: 959-60
49. Heffler, E., Detoraki, A., Contoli, M., et al. 2021. COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. Allergy 76: 887-92
50. Matucci, A., Caminati, M., Vivarelli, E., et al. 2021. COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy 76: 871-4
51. Eger, K., Hashimoto, S., Braunstahl, G. J., et al. 2020. Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. Respir Med 177: 106287
52. Eggert, L. E., He, Z., Collins, W., et al. 2021. Asthma phenotypes, associated comorbidities, and long-term symptoms in COVID-19. Allergy in press, doi:10.1111/all.14972
53. Wang, L., Foer, D., Bates, D. W., et al. 2020. Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19. J Allergy Clin Immunol 146: 808-12
54. Bloom, C. I., Drake, T. M., Docherty, A. B., et al. 2021. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med 9: 699-711
55. Calmes, D., Graff, S., Maes, N., et al. 2021. Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection. J Allergy Clin Immunol Pract 9: 160-9
56. Antonicelli, L., Tontini, C., Manzotti, G., et al. 2021. Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry. Allergy 76: 902-5
57. Skevaki, C., Karsonova, A., Karaulov, A., et al. 2021. SARS-CoV-2 infection and COVID-19 in asthmatics: a complex relationship. Nat Rev Immunol 21: 202-3
58. Beken, B., Ozturk, G. K., Aygun, F. D., et al. 2021. Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019. Ann Allergy Asthma Immunol 126: 569-75
59. Du, H., Dong, X., Zhang, J. J., et al. 2020. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Allergy 76:510.
60. Licari, A., Votto, M., Brambilla, I., et al. 2020. Allergy and asthma in children and adolescents during the COVID outbreak: What we know and how we could prevent allergy and asthma flares. Allergy 75: 2402-5
61. Metbulut, A. P., Mustafaoğlu, O., Sen, G., et al. 2021. Evaluation of the Clinical and Laboratory Findings of Asthmatic Children with SARS-CoV-2 Infection. Int Arch Allergy Immunol: 1-8
62. Papadopoulos, N. G., Mathioudakis, A. G., Custovic, A., et al. 2021. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort. *Allergy* 76: 1765-75

63. Brindisi, G., De Vittori, V., De Nola, R., et al. 2021. Updates on Children with Allergic Rhinitis and Asthma during the COVID-19 Outbreak. *J Clin Med* 10:2278

64. O’Beirne, S. L., Salit, J., Kaner, R. J., et al. 2021. Up-regulation of ACE2, the SARS-CoV-2 receptor, in asthmatics on maintenance inhaled corticosteroids. *Respiratory Research* 22: 200

65. Schultze, A., Walker, A. J., MacKenna, B., et al. 2020. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. *Lancet Respir Med* 8: 1106-20

66. Matsuyama, S., Kawase, M., Nao, N., et al. 2020. The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. *J Virol* 95

67. Klimek, L., Akdis, C. A., Jutel, M., et al. 2021. Inhaled Corticosteroids in early COVID-19 - a tale of many facets. *Allergy* in press, doi:10.1111/all.15041

68. Adir, Y., Humbert, M., Saliba, W. 2021. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence. *J Allergy Clin Immunol* 148: 361-7 e13

69. Williamson, E. J., Walker, A. J., Bhaskaran, K., et al. 2020. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 584: 430-6

70. Hasan, S. S., Capstick, T., Zaidi, S. T. R., et al. 2020. Use of corticosteroids in asthma and COPD patients with or without COVID-19. *Respir Med* 170: 106045

71. Kumar, K., Hinks, T. S. C., Singanayagam, A. 2020. Treatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used? *Am J Physiol Lung Cell Mol Physiol* 318: L1244-L7

72. Bousquet, J., Jutel, M., Akdis, C. A., et al. 2021. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). *Allergy* 76: 689-97

73. Brindisi, G., De Vittori, V., De Castro, G., et al. 2020. Pills to think about in allergic rhinitis children during COVID-19 era. *Acta Paediatr* 109: 2149-50

74. Choi, Y. J., Park, J. Y., Lee, H. S., et al. 2021. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. *Eur Respir J* 57:2002226.

75. Huynh, T., Wang, H., Luan, B. 2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2’s Main Protease. *J Phys Chem Lett* 11:4413-20

76. Khan, A. R., Misdary, C., Yegya-Raman, N., et al. 2021. Montelukast in hospitalized patients diagnosed with COVID-19. *J Asthma*: 1-7

77. Barre, J., Sabatier, J. M., Annweiler, C. 2020. Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence. *Front Pharmacol* 11: 1344

78. Vasanthakumar, N. 2020. Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients. *Bioessays* 42: e2000094

79. Hanon, S., Brusselle, G., Deschampheleire, M., et al. 2020. COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry. *Eur Respir J* 56:2002857.

80. Rial, M. J., Valverde, M., Del Pozo, V., et al. 2021. Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak. *J Allergy Clin Immunol Pract* 9: 487-9 e1

81. Lommatzsch, M., Stoll, P., Virchow, J. C. 2020. COVID-19 in a patient with severe asthma treated with Omalizumab. *Allergy* 75: 2705-8

82. Akku, K., Yesilkaya, S., Topel, M., et al. 2021. COVID-19 in a patient with severe asthma using mepolizumab. *Allergy Asthma Proc* 42: e55-e7
83. Renner, A., Marth, K., Patocka, K., et al. 2020. COVID-19 in a severe eosinophilic asthmatic receiving benralizumab - a case study. *J Asthma* 1-3
84. Bhalla, A., Mukherjee, M., Radford, K., et al. 2021. Dupilumab, severe asthma airway responses, and SARS-CoV-2 serology. *Allergy* 76: 957-8
85. Gill, M. A., Liu, A. H., Calatroni, A., et al. 2018. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. *J Allergy Clin Immunol* 141: 1735-43 e9
86. Xie, G., Ding, F., Han, L., et al. 2021. The role of peripheral blood eosinophil counts in COVID-19 patients. *Allergy* 76: 471-82
87. Zhao, L., Zhang, Y. P., Yang, X., et al. 2021. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019. *Allergy* 76: 562-4
88. Liuzzo Scorpo, M., Ferrante, G., La Grutta, S. 2021. An Overview of Asthma and COVID-19: Protective Factors Against SARS-COV-2 in Pediatric Patients. *Front Pediatr* 9: 661206
89. Ferastaeroaru, D., Hudes, G., Jerschow, E., et al. 2021. Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness. *J Allergy Clin Immunol* 9: 1152-62 e3
90. Jesenak, M., Banovcin, P., Diamant, Z. 2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils-Observations from reported clinical case series. *Allergy* 75: 1819-22
91. Drake, M. G., Fryer, A. D., Jacoby, D. B. 2021. Protective effects of eosinophils against COVID-19: More than an ACE(2) in the hole? *J Allergy Clin Immunol Pract* 9: 2539-40
92. Azim, A., Pini, L., Khakwani, Z., et al. 2021. Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy. *Ann Allergy Asthma Immunol* 126: 438-40
93. Skevaki, C., Hudemann, C., Matrosovich, M., et al. 2018. Influenza A virus infection in those on mepolizumab therapy. *Allergy* 73: 1819-22
94. Balz, K., Kaushik, A., Chen, M., et al. 2021. Homologies between SARS-CoV-2 and allergen proteins may direct T cell-mediated heterologous immune responses. Sci Rep 11: 4792
95. Farne, H., Singanayagam, A. 2020. Why asthma might surprisingly protect against poor outcomes in COVID-19. *Eur Respir J* 56: 20003045.
96. Chavasse, R. J. 2020. Covid-19: reduced asthma presentations in children. *BMJ* 370: m2806
97. Ferreli, F., Gaino, F., Russo, E., et al. 2020. Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis. *J Allergy Clin Immunol Pract* 8: 3587-9
98. Hagemann, J., Onorato, G. L., Jutel, M., et al. 2021. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA(2) LEN consensus. *Allergy* 76: 2354-66
99. Bruno, C., Locatello, L. G., Cilona, M., et al. 2020. Seasonal Allergic Rhinitis Symptoms in Relation to COVID-19. *Allergy Rhinol (Providence)* 11: 2152656720968804
100. Gelardi, M., Trecca, E., Fortunato, F., et al. 2021. COVID-19 lockdown and seasonal allergic rhinitis: our experience in 40 patients. *Acta Biomed* 92: e2021215
101. Wang, H., Song, J., Yao, Y., et al. 2021. Angiotensin-converting enzyme II expression and its implication in the association between COVID-19 and allergic rhinitis. *Allergy* 76: 906-10
102. Guvey, A. 2021. How does allergic rhinitis impact the severity of COVID-19?: a case-control study. *Eur Arch Otorhinolaryngol* in press, doi:10.1007/s00405-021-06836-z.
103. Marin, C., Tubita, V., Langdon, C., et al. 2021. ACE2 downregulation in olfactory mucosa: Eosinophilic rhinosinusitis as COVID-19 protective factor? *Allergy* in press, doi:10.1111/all.14904
104. Wang, H., Song, J., Pan, L., et al. 2021. Regional differences in ACE2 expression in the sinonasal mucosa of adult Chinese patients with chronic rhinosinusitis. *Allergy* 76: 1565-8
105. Scadding, G. K., Hellings, P. W., Bachert, C., et al. 2020. Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement. *World Allergy Organ J* 13: 100124
106. Dror, A. A., Eisenbach, N., Marshak, T., et al. 2020. Reduction of allergic rhinitis symptoms with face mask usage during the COVID-19 pandemic. *J Allergy Clin Immunol Pract* 8: 3590-3
107. Bousquet, J., Akdis, C., Jutel, M., et al. 2020. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. *Allergy* in press, doi:10.1111.all.14302

108. Islak, A., Balci, M. K. 2021. Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire. *Pharmacol Rep* 73: 781-5

109. Nakazono, A., Nakamaru, Y., Ramezanpour, M., et al. 2021. Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells. *Front Cell Infect Microbiol* 11: 655666

110. Yegit, O. O., Demir, S., Unal, D., et al. 2021. Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic. *Allergy* in press, doi:10.1111/all.14876

111. Daneshgaran, G., Dubin, D. P., Gould, D. J. 2020. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. *Am J Clin Dermatol* 21: 627-39

112. Kearns, D. G., Uppal, S., Chat, V. S., et al. 2020. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic. *J Am Acad Dermatol* 83: e251-e2

113. Wollenberg, A., Flohr, C., Simon, D., et al. 2020. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and atopic dermatitis. *J Eur Acad Dermatol Venereol* 34: e241-e2

114. Patsatsi, A., Kyriakou, A. 2021. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence? *Clin Dermatol* 39: 52-5

115. Souaid, K., Klejtmans, T., Kramkimel, N., et al. 2021. Topical steroids and topical tacrolimus appear safe regarding the COVID-19 epidemic. *Ann Dermatol Venereol* 148: 122-3

116. Keswani, A., Dhana, K., Rosenthal, J. A., et al. 2020. Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019. *Ann Allergy Asthma Immunol* 125: 479-81

117. Chen, G., DunnGalvin, A., Campbell, D. E. 2021. Impact of COVID-19 pandemic on quality of life for children and adolescents with food allergy. *Clin Exp Allergy* in press, doi:10.1111/cea.13973

118. Musallam, N., Dalal, I., Almog, M., et al. 2021. Food allergic reactions during the Covid-19 pandemic lockdown in Israeli children. *Pediatr Allergy Immunol* in press, doi:10.1111/pai.13540

119. Mack, D. P., Chan, E. S., Shaker, M., et al. 2020. Novel Approaches to Food Allergy Management During COVID-19 Inspire Long-Term Change. *J Allergy Clin Immunol Pract* 8: 2851-7

120. Mitamura, Y., Schulz, D., Oro, S., et al. 2021. Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients. *Allergy* in press, doi:10.1111/all.14983

121. Novak, N., Peng, W., Naegeli, M. C., et al. 2021. SARS-CoV-2, COVID-19, skin and immunology - What do we know so far? *Allergy* 76: 698-713

122. Gelincik, A., Brockow, K., Celik, G. E., et al. 2020. Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. *Allergy* 75: 2775-93

123. Sokolowska, M., Eiwegger, T., Ollert, M., et al. 2021. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. *Allergy* 76: 1629-39

124. Bousquet, J., Agache, I., Blain, H., et al. 2021. Management of anaphylaxis due to COVID-19 vaccines in the elderly. *Allergy* in press, doi:10.1111/all.14838

125. Klimek, L., Jutel, M., Akdis, C. A., et al. 2021. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper. *Allergy* 76: 1624-8

126. Kocaturk, E., Salman, A., Cherrez-Ojeda, I., et al. 2021. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. *Allergy* 76: 816-30
127. Passante, M., Napolitano, M., Dastoli, S., et al. 2021. Safety of omalizumab treatment in patients with chronic spontaneous urticaria and COVID-19. *Dermatol Ther* in press. Doi:10.1111.dth.15111

128. Smola, A., Samadzadeh, S., Muller, L., et al. 2021. Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine. *J Eur Acad Dermatol Venereol* 35:e743.

129. Klimek, L., Jutel, M., Akdis, C., et al. 2020. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. *Allergy* 75: 1546-54

130. Brough, H. A., Kalayci, O., Sediva, A., et al. 2020. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics - The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics. *Pediatr Allergy Immunol* 31: 442-8

131. Vultaggio, A., Agache, I., Akdis, C. A., et al. 2020. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. *Allergy* 75: 2764-74

132. Pfaar, O., Klimek, L., Jutel, M., et al. 2021. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. *Allergy* 76: 648-76

133. Klimek, L., Jutel, M., Bousquet, J., et al. 2021. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper. *Allergy* 76: 677-88
Table 1. Prevalence of asthma in adult COVID-19 patients

| Location                  | Asthma in COVID-19, n (%) | Asthma prevalence in general population (%) | References |
|---------------------------|---------------------------|---------------------------------------------|------------|
| Mexico                    | 3.6                       | 5.0                                         | (25)       |
| Wuhan, China              | 0/140 (0)                 | 6.4                                         | (26)       |
| Wuhan, China              | 5/548 (0.9)               | 6.4                                         | (27)       |
| Paris, France             | 37/786 (4.8)              | 7.0                                         | (28)       |
| Israel                    | 153/2666 (6.75)           | 9.62                                        | (29)       |
| Brescia and Verona, Italy | 20/1043 (1.92) in Brescia and 6/305 (1.96) in hospitalized COVID-19 patients | 6.1 in Brescia, 6.0 in Verona | (30)       |
| Saudi Arabia              | 4/150 (2.7)               | 8.2                                         | (31)       |
| Brazil                    | Moderate to severe asthma, 1.5% of 51700 COVID-19 cases | 13.9 | (32) |
| Madrid, Spain             | 11/189 (5.8)              | 7.0                                         | (33)       |
| Madrid, Spain             | 116/2226 (5.2)            | 7.0                                         | (34)       |
| Russia                    | 23/1307 (1.8)             | 6.9                                         | (35)       |
| Switzerland               | 204/2411 (8.5)            | 2.8                                         | (36)       |
| Strasbourg, France        | 23/106 (21.7)             | 7.0                                         | (37)       |
| UK                        | 14.0-17.9                 | 13-13.5                                     | (38)       |
| Sweden                    | 4493/68575 (6.6)          | 6.4                                         | (39)       |
| Korea                     | 725/7340 (9.9)            | 2.2                                         | (40)       |
| Daegu, Korea              | 3.2% of 2200 COVID-19 patients | 2.2 | (41) |
| Korea                     | 96/4057 (2.3)             | 2.2                                         | (42)       |
| New York, USA             | 4.4                       | 6.8                                         | (43)       |
| New York, USA             | 163/1298 (12.6) (< 65 years, including children) | 6.8 | (44) |
| California, USA           | 5526/61338 (9.0), active asthma: 4.5; inactive asthma: 4.5 | 8.9-10.1 | (45) |
| New York, USA             | 232/5973 (4.7)            | 6.8                                         | (46)       |
Table 2. Impact of preexisting asthma on the outcomes of COVID-19 patients.

| Location          | Impacts of asthma on COVID-19 outcomes                                                                                       | References |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------|------------|
| Paris, France     | Asthma was not associated with increased mortality of COVID-19. (Asthma 8.1% vs. control 14.6%)                              | (28)       |
| Strasbourg, France| Asthma did not induce severe COVID-19. aOR, 1.065 (95% CI, 0.272-3.522). And COVID-19 did not induce severe asthma exacerbation.| (37)       |
| Sweden            | Asthma was associated with increased hospitalization rate but not mortality.                                                      | (39)       |
| Daegu, Korea.     | Asthma was not associated with clinical outcomes of COVID-19.                                                                     | (41)       |
| Korea             | Asthma patients older than 50 years (aHR 2.22, 95%CI: 1.03-4.76) and female asthma patients (aHR 3.74, 95% CI: 1.35-10.35) had increased risk of death due to COVID-19. | (42)       |
| USA               | Asthma was not associated with an increased risk of hospitalization.                                                            | (43)       |
| New York, USA     | In COVID-19 patients < 65 years, asthma was not a risk factor for severity and mortality.                                     | (44)       |
| California, USA   | Active asthma, especially the ones without proper medication, had higher risk of COVID-19-related hospitalization, intensive respiratory support and ICU stay, but had no increased mortality. | (45)       |
| Italy             | Severe asthma did not increase severe outcomes of COVID-19.                                                                     | (50)       |
| Nederland         | Severe asthma receiving biologicals were associated with higher risk of hospitalization and intubation.                       | (51)       |
| USA               | Asthma was not a risk factor for hospitalization, and allergic asthma was associated with lower hospitalization of COVID-19. | (52)       |
| USA               | Asthma patients solely using SABA to relieve symptoms were associated with lower risk of hospitalization                         | (53)       |
| UK                | Asthma was associated with severe disease; in addition, severe asthma was associated with increased mortality of COVID-19.    | (54)       |
| Belgium           | Asthma was not a risk factor for ICU admission and mortality.                                                                   | (55)       |
| Italy             | Severe asthma did not increase severe outcomes of COVID-19.                                                                     | (56)       |
| New York, USA     | Asthma was not a risk factor for mortality of COVID-19. OR 0.89 (95%CI, 0.65-1.21).                                             | (58)       |
| Korea             | Asthma was associated with severe clinical outcomes, mainly caused by non-allergic asthma.                                     | (40)       |
Table 3. Interactions of asthma, allergy with COVID-19 in children.

| Topic                                      | Main findings                                                                                                                                                                                                 | References |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Prevalence of allergy and asthma in 107 COVID-19 children. | The prevalence of AR, asthma, AD and episodic wheezing were 10.3%, 6.5%, 4.7% and 3.7% respectively in pediatric COVID-19 patients. Asthma and allergy are not risk factors for hospitalization of COVID-19. | (58)       |
| 182 pediatric COVID-19 cases.             | Allergy did not impact disease incidence, clinical features, laboratory and immunological findings of COVID-19, and was not a risk factor for infection and severity of COVID-19 in children.                                | (59)       |
| Prevalence of allergy and asthma in 40 COVID-19 children. | Prevalence of allergy was 5.0% in COVID-19 children, lower than that in pediatric population (32.2%). Prevalence of asthma was 2.5% and lower than that in pediatric population (11.6%). |
| Asthma children with COVID-19.           | Children with asthma had more symptoms of COVID-19 and higher rate of hospitalization, but no difference in the severity and laboratory findings compared to children without asthma.                             | (61)       |
| Childhood asthma outcomes during COVID-19. | Childhood with asthma had a better asthma control and improved lung function during COVID-19, may be due to reduced exposure to triggers.                                                                    | (62)       |
| Children with AR and Asthma during COVID-19. | A general trend of clinical improvement and a reduction in the use of on-demand and basal therapy in allergic children during the lockdown.                                                                     | (63)       |
Table 4. Impact of currently available asthma treatments on COVID-19.

| Treatments | Impacts on COVID-19 | References |
|------------|---------------------|------------|
| ICS        | Increase ACE2 expression in large airway epithelium. | (64) |
| Ongoing use of ICS did not increase the hospitalization rate of COVID. | (43) |
| High-dose ICS treatment was associated with higher death rate of COVID-19. | (65) |
| Asthma patients older than 50 years and treated with ICS alone within 2 weeks of COVID-19 hospitalization had a reduced mortality compared to those without chronic pulmonary disease. | (54) |
| ICS use before hospitalization did not increase the risk of ICU admission and death. | (55) |
| OCS        | OCS use during the last 12 months did not increase COVID-19 infection. | (29, 68) |
| OCS use during the last 12 months increased the severity and mortality of COVID-19; recent use (within 120 days) of OCS was a risk factor for COVID-19 severity and mortality. | (68) |
| OCS use within 2 weeks prior to admission increased the death rate of COVID-19 | (69) |
| OCS use before hospitalization did not increase the risk of ICU admission and death. | (55) |
| For asthma patients relying on OCS to control symptoms, OCS may be beneficial. | (70) |
| LABA       | No data about LABA use alone on COVID-19. | (74) |
| ICS+LABA treatment in the last 12 months did not affect the infection, severity, and mortality of COVID-19. | (43) |
| ICS+LABA-treated asthma patients had a higher hospitalization rate than those treated with ICS only and a higher ICU admission rate than those treated without ICS+LABA or with ICS only. | (63) |
| SABA       | SABA use alone for asthma control had no impact on COVID-19 mortality. | (54) |
| Inhaled SABA only for asthma control in the previous 4 months reduced COVID-19 mortality. | (65) |
| LTRA       | Long-term treatment of montelukast reduced infection and hospitalization rate and clinical deterioration rate of COVID-19. | (76) |
| Montelukast had no impact on COVID-19 susceptibility. | (29) |
| LTRA did not increase COVID-19 mortality. | (74) |
| Biologicals | Treatment of severe asthma with biologicals did not increase infection and severity of COVID-19. | (79) |
| Severe asthma treated with biologicals did not increase the severity and mortality of COVID-19. | (68,80,81) |
| Poor outcomes of COVID-19 in asthma patients treated with biologicals. | (51) |
| A severe asthma patient treated with Dupilumab had a modest antibody response against SARS-CoV-2. | (84) |
Table 5 EAACI position papers on the management of allergic diseases during COVID-19.

| Allergic disease or topics | Recommendations                                                                                                                                                                                                 | References |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Asthma                     | ICS or OCS should continue. Spacers of large capacity are recommended to replace nebulizer for active infectants.                                                                                               | (72)       |
| Intranasal corticosteroids in AR in COVID-19 | In COVID-19 patients, intranasal corticosteroids (including spray) can be continued in AR at the recommended dose.                                                                                                             | (107)      |
| Drug allergy               | All available information about drug hypersensitivity reactions due to current and candidate off-label drugs to treat COVID-19.                                                                                       | (122)      |
| Severe allergic reactions to COVID-19 vaccines | Milder and moderate reactions should not be excluded from the vaccination; Recognize and treat anaphylaxis, including administering adrenalin properly; at least 15 min observation period following vaccination; AR and asthma are not at higher risk of severe allergic reactions to COVID-19 vaccines. | (125)      |
| Handling of AIT during COVID-19 | Both SCIT and SLIT can be continued in COVID-19 pandemics in uninfected individuals, in suspected individuals with negative test result (RT-PCR) or after an adequate quarantine, or convalescent patients with detection of serum IgG to SARS-CoV-2 without virus-specific IgM. | (129)      |
| Managing childhood allergies during COVID-19 | Gain the best control of current allergic symptoms and reduce the risk of COVID-19 infection; reduce stress levels of the children and their parents; be aware of the difference of COVID-19 and seasonal allergy; Treat allergies according to usual guidelines; recommend using pMDI but not nebulizer. | (130)      |
| Biologicals use during COVID-19 | Noninfected patients on biologicals for the treatment of allergic diseases should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be reinitiated. | (131)      |
| Organization of an allergy clinic | Recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic                                                                 | (132)      |
| Management of chronic rhinosinusitis during COVID-19 | Intranasal corticosteroids remain the standard treatment for CRS in COVID-19 patients. Surgery should be reduced to a minimum and preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Biologicals can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during COVID-19. | (133)      |